Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 4/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.62 |
| ▸ | ACHE | P22303 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828789 | 0.86 | CLK2 (0.66) | CLK2ESR1ESR2NPSR1RXFP1 | |
| SCHEMBL26768200 | 0.84 | ESR1 (0.63) | CLK2ESR1ESR2ACHEMAOA | |
| SCHEMBL31059962 | 0.83 | MGAM (0.64) | CLK2ESR1ESR2ACHENPSR1 | |
| SCHEMBL26779740 | 0.83 | MGAM (0.64) | CLK2ESR1ESR2ACHENPSR1 | |
| SCHEMBL26767091 | 0.81 | ACHE (0.57) | ESR1ESR2ACHENPSR1RXFP1 | |
| SCHEMBL9837650 | 0.79 | MGAM (0.72) | CLK2ESR2MAOANUAK1IGF1R | |
| SCHEMBL26768132 | 0.78 | ESR1 (0.81) | CLK2ESR1ESR2MAOANUAK1 | |
| SCHEMBL17177077 | 0.78 | KDM4E (0.49) | ESR2GAAALDH1A1HPGDHSD17B10 | |
| SCHEMBL11217107 | 0.78 | CLK2 (0.63) | CLK2ESR1ESR2MAOANUAK1 | |
| Alternariol SCHEMBL29423320 | 0.77 | CLK2 (1.00) | CLK2ESR1ESR2MAOANUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | CLK2 3834/4885ESR1 4838/4885ESR2 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.